-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on UroGen Pharma, Lowers Price Target to $15

Benzinga·05/23/2025 14:45:47
Listen to the news
Guggenheim analyst Michael Schmidt maintains UroGen Pharma (NASDAQ:URGN) with a Buy and lowers the price target from $40 to $15.